Johns Hopkins and other researchers report what is believed to be the first direct evidence in lab animals that the erectile dysfunction drug sildenafil amplifies the effects of a heart-protective protein.
The team’s findings, to be published in the Journal of Clinical Investigation online Jan. 5, helps explain why sildenafil, more widely Read more…
Health Canada is warning consumers not to use Rize 2 The Occasion capsules (Rize2), an unauthorized product promoted for the treatment of erectile dysfunction, because it may pose serious health risks. Rize 2 contains an undeclared pharmaceutical ingredient similar to the prescription drug sildenafil which should only be used under Read more…
FDA Requests Recall Of Xiadafil VIP Tabs
The U.S. generic amoxil online buy Food and Drug Administration requested that SEI Pharmaceuticals, of Miami, Fla., recall all Xiadafil VIP Tabs sold in 8 tablet bottles (Lot # 6K029) or blister cards of 2 tablets (Lot # 6K029-SEI) because these products contain a potentially harmful, undeclared ingredient that may dangerously affect a person’s Read more…
Federal Authorities Seize Xiadafil VIP Tablets After Company Refuses To Recall Product, USA
At the request of the U.S. Food and Drug Administration, U.S. Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Fla. Although marketed as a dietary supplement to treat erectile dysfunction (ED) and for sexual enhancement, these lots represent an illegally marketed drug containing Read more…
FDA Requests Recall Of Xiadafil VIP Tabs
The U.S. Food and Drug Administration requested that SEI Pharmaceuticals, of Miami, Fla., recall all Xiadafil VIP Tabs sold in 8 tablet bottles (Lot # 6K029) or blister cards of 2 tablets (Lot # 6K029-SEI) because these products contain a potentially harmful, undeclared ingredient that may dangerously affect a person’s blood pressure and can cause other life-threatening side effects. These lots of Xiadafil Read more…
UroToday.com - A group from the UK led by Bridget Candy report a meta-analysis in the BJU International on phosphodiesterase type 5 inhibitors (PDE5i) for the treatment of erectile dysfunction (ED) secondary to treatments for prostate cancer (CaP).
Only randomized controlled trials were included and outcomes Read more…
UroToday.com - This a randomized, double-blind, placebo controlled, parallel group, multicenter study involving 200 men with or without erectile dysfunction. Men (25-64 years of age) did not have ejaculatory dysfunction. Subjects were randomized to daily Read more…